MX367082B - Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. - Google Patents
Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.Info
- Publication number
- MX367082B MX367082B MX2015005481A MX2015005481A MX367082B MX 367082 B MX367082 B MX 367082B MX 2015005481 A MX2015005481 A MX 2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A MX 367082 B MX367082 B MX 367082B
- Authority
- MX
- Mexico
- Prior art keywords
- aureus
- methods
- treating
- preventing
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723128P | 2012-11-06 | 2012-11-06 | |
| PCT/US2013/068385 WO2014074470A1 (en) | 2012-11-06 | 2013-11-05 | Methods of treating s. aureus-associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015005481A MX2015005481A (es) | 2016-01-14 |
| MX367082B true MX367082B (es) | 2019-08-05 |
Family
ID=50685101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015005481A MX367082B (es) | 2012-11-06 | 2013-11-05 | Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9845348B2 (enExample) |
| EP (1) | EP2928490B1 (enExample) |
| JP (2) | JP6506172B2 (enExample) |
| KR (3) | KR20150092738A (enExample) |
| CN (2) | CN112316135A (enExample) |
| AU (2) | AU2013341421A1 (enExample) |
| BR (1) | BR112015010126B1 (enExample) |
| CA (1) | CA2890385C (enExample) |
| ES (1) | ES2912267T3 (enExample) |
| MX (1) | MX367082B (enExample) |
| RU (1) | RU2661406C2 (enExample) |
| SG (2) | SG10201703677VA (enExample) |
| WO (1) | WO2014074470A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102111171B1 (ko) | 2011-06-10 | 2020-05-14 | 메디뮨 엘엘씨 | 항슈도모나스 ｐｓｌ 결합 분자 및 그의 용도 |
| SMT202000542T1 (it) | 2011-11-07 | 2020-11-10 | Medimmune Ltd | Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas |
| CA2890427C (en) | 2012-11-06 | 2022-05-31 | Medimmune, Llc | Antibodies to s. aureus surface determinants |
| SG10201703677VA (en) * | 2012-11-06 | 2017-06-29 | Medimmune Llc | Methods of treating s. aureus-associated diseases |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| TWI781130B (zh) | 2017-01-03 | 2022-10-21 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| CN119176871A (zh) | 2018-07-24 | 2024-12-24 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌凝集因子a(clfa)的抗体 |
| WO2020076789A2 (en) | 2018-10-09 | 2020-04-16 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| MX2021004114A (es) | 2018-10-09 | 2021-07-16 | Medimmune Llc | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. |
| TW202100549A (zh) | 2019-03-13 | 2021-01-01 | 美商麥迪紐有限責任公司 | 降低金黃色葡萄球菌在定殖的患者中之感染 |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007259415B2 (en) * | 2006-06-12 | 2013-09-26 | Glaxosmithkline Biologicals Sa | Use of alpha-toxin for treating and preventing Staphylococcus infections |
| CA2697538C (en) * | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| WO2011008939A2 (en) * | 2009-07-16 | 2011-01-20 | Medical College Of Georgia Research Institute, Inc. | Porous-wall hollow glass microspheres as carriers for biomolecules |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| AU2012214677B2 (en) * | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| PT2673373T (pt) | 2011-02-08 | 2018-12-05 | Medimmune Llc | Anticorpos que ligam especificamente a toxina alfa de staphylococcus aureus e métodos de utilização |
| CA2890427C (en) | 2012-11-06 | 2022-05-31 | Medimmune, Llc | Antibodies to s. aureus surface determinants |
| SG10201703677VA (en) * | 2012-11-06 | 2017-06-29 | Medimmune Llc | Methods of treating s. aureus-associated diseases |
| TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
| US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
-
2013
- 2013-11-05 SG SG10201703677VA patent/SG10201703677VA/en unknown
- 2013-11-05 CA CA2890385A patent/CA2890385C/en active Active
- 2013-11-05 KR KR1020157011460A patent/KR20150092738A/ko not_active Ceased
- 2013-11-05 RU RU2015121617A patent/RU2661406C2/ru active
- 2013-11-05 KR KR1020217020104A patent/KR20210083389A/ko not_active Ceased
- 2013-11-05 SG SG11201503231YA patent/SG11201503231YA/en unknown
- 2013-11-05 KR KR1020207024078A patent/KR102272744B1/ko active Active
- 2013-11-05 MX MX2015005481A patent/MX367082B/es active IP Right Grant
- 2013-11-05 ES ES13853844T patent/ES2912267T3/es active Active
- 2013-11-05 CN CN202011217117.7A patent/CN112316135A/zh active Pending
- 2013-11-05 WO PCT/US2013/068385 patent/WO2014074470A1/en not_active Ceased
- 2013-11-05 CN CN201380057604.3A patent/CN104780934A/zh active Pending
- 2013-11-05 AU AU2013341421A patent/AU2013341421A1/en not_active Abandoned
- 2013-11-05 US US14/440,749 patent/US9845348B2/en active Active
- 2013-11-05 BR BR112015010126-7A patent/BR112015010126B1/pt active IP Right Grant
- 2013-11-05 JP JP2015540852A patent/JP6506172B2/ja active Active
- 2013-11-05 EP EP13853844.2A patent/EP2928490B1/en active Active
-
2017
- 2017-12-18 US US15/845,701 patent/US10457724B2/en active Active
-
2018
- 2018-09-28 AU AU2018236849A patent/AU2018236849B2/en active Active
-
2019
- 2019-03-28 JP JP2019063358A patent/JP6926138B2/ja active Active
- 2019-10-11 US US16/599,595 patent/US10759849B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX367082B (es) | Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. | |
| NZ709997A (en) | Methods for treating conditions associated with masp-2 dependent complement activation | |
| NZ630363A (en) | Anti-kit antibodies and uses thereof | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| MX2015006681A (es) | Formulaciones de vancomicina estabilizadas. | |
| WO2013119716A8 (en) | Compositions and methods for using csf1r inhibitors | |
| UA115034C2 (uk) | Імунокон'югат для застосування в лікуванні раку або запального порушення | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| MX2020009700A (es) | Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso. | |
| MX2018010776A (es) | Moleculas de union de antigeno multiespecificas y usos de las mismas. | |
| PH12013500277A1 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
| BR112015010125A2 (pt) | Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente | |
| EP4516811A3 (en) | Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses | |
| HK1200463A1 (en) | Human antibodies to clostridium difficile toxins | |
| MX2015007147A (es) | Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab. | |
| PT2594588E (pt) | Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou andaime proteico não ig anti-adm para utilização em terapia | |
| BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| SG10201804809RA (en) | Clostridium difficile antibodies | |
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| GB201109238D0 (en) | Antibodies | |
| MX357708B (es) | Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro. | |
| AU2018256482A1 (en) | Antibodies Against Clostridium Difficile | |
| HK1207970A1 (en) | Agents for influenza neutralization | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |